Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2011

01-10-2011 | Preclinical study

Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma

Authors: Kathryn C. Behling, Amy Tang, Boris Freydin, Inna Chervoneva, Sameep Kadakia, Gordon F. Schwartz, Hallgeir Rui, Agnieszka K. Witkiewicz

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Login to get access

Abstract

Hyperactivated HER2/Neu/EGFR/RAS signaling is a major growth-promoting pathway known to drive cellular transformation and oncogenesis in breast cancers. HER2 amplification is detected in ~20% of all human breast cancer and is quite prevalent (up to 49%) in ductal carcinoma in situ (DCIS). The E3 ubiquitin ligase SIAH is considered a key downstream “gatekeeper” required for proper HER2/EGFR/RAS signal transduction. Formalin-fixed, paraffin-embedded resection specimens from 65 patients with DCIS treated with wide excision only were stained with an anti-SIAH antibody, and the percentage of tumor and normal adjacent tissue cells positive for SIAH nuclear staining were recorded. Statistical analysis was performed comparing SIAH staining in tumor cells to disease recurrence, histologic type, necrosis, hormone receptor status, and Her2/neu status, as well as nuclear grade. Correlation of SIAH expression in tumor cells with SIAH expression in normal adjacent tissue and age was also examined. Expression levels of SIAH in tumor cells was significantly higher in specimens from patients with recurrence (median = 19%) as compared to patients without recurrence (7%) (P < 0.001). There was also significantly increased SIAH expression in tumors with more aggressive features including comedo morphology (13.5% in comedo vs. 7% in other histologic types, P = 0.014). No significant association was observed between SIAH expression and estrogen receptor, progesterone receptor, and Her2/neu status. There was a significant correlation between SIAH expression in tumors and normal adjacent tissue (Spearman correlation = 0.58, P < 0.001) as well as between SIAH expression in normal adjacent tissue and patient age (Spearman correlation = −0.59, P < 0.001). No significant correlation was identified between patient age and SIAH expression in tumors (Spearman correlation = −0.23, P = 0.067). In conclusion, SIAH may represent a useful prognostic biomarker that predicts DCIS progression to invasive breast cancer.
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249PubMedCrossRef
2.
Virnig BA, Tuttle TM, Shamliya T, Kane RL (2010) Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102:170–178PubMedCrossRef
3.
Sakorafas GH, Farley DR, Peros G (2008) Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev 34(6):483–497PubMedCrossRef
4.
Valenzuela M, Julian TB (2007) Ductal carcinoma in situ: biology, diagnosis, and new therapies. Clin Breast Cancer 7:676–681PubMedCrossRef
5.
Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103(12):2481–2484PubMedCrossRef
6.
Carthew RW, Rubin GM (1990) Seven in absentia, a gene required for specification of R7 cell fate in the Drosophila eye. Cell 63:561–577PubMedCrossRef
7.
Tang AH, Neufeld TP, Kwan E, Rubin GM (1997) PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism. Cell 90:459–467PubMedCrossRef
8.
House CM, Möller A, Bowtell DD (2009) Siah proteins: novel drug targets in the Ras and hypoxia pathways. Cancer Res 69(23):8835–8838PubMedCrossRef
9.
Schmidt RL, Park CH, Ahmed AU, Gundelach JH, Reed NR, Cheng S, Knudsen BE, Tang AH (2007) Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue. Cancer Res 67(24):11798–11810PubMedCrossRef
10.
Ahmed AU, Schmidt RL, Park CH, Reed NR, Hesse SE, Thomas CF, Molina JR, Deschamps C, Yang P, Aubry MC, Tang AH (2008) Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. J Natl Cancer Inst 100(22):1606–1629PubMedCrossRef
11.
Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, Mehdom HM, Davis G, Steinberg SM, Meltzer PS, Aldape K, Steeq PS (2009) Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 7(9):1438–1445PubMedCrossRef
12.
Roh MS, Hong SH, Jeong JS, Kwon HC, Kim MC, Cho SH, Yoon JH, Hwang TH (2004) Gene expression profiling of breast cancers with emphasis of beta-catenin regulation. J Korean Med Sci 19(2):275–282PubMedCrossRef
13.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072PubMedCrossRef
14.
Collins LC, Achacoso N, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP Jr, Puligandla B, Alshak NS, Goldstein LC, Gown AM, Schnitt SJ, Habel LA (2009) Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol 33(12):1802–1808PubMedCrossRef
15.
Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG (2003) Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97(6):1393–1403PubMedCrossRef
16.
Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R (2004) The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 100(11):2317–2327PubMedCrossRef
17.
Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New York, pp 346–347
18.
Peduzzi PN, Concato J, Kemper E, Holford TR, Feinstein A (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 99:1373–1379CrossRef
19.
Tsikitis VL, Chung MA (2006) Biology of ductal carcinoma in situ classification based on biologic potential. Am J Clin Oncol 29(3):305–310PubMedCrossRef
20.
Ding L, Kleer CG (2006) Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 66(19):9352–9355PubMedCrossRef
21.
Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG (2006) Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 66(8):4095–4099PubMedCrossRef
22.
Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, Bloom G, Anderson T, White J, Quackenbush J, Yeatman T (2010) Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat 119(2):335–346PubMedCrossRef
Metadata
Title
Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma
Authors
Kathryn C. Behling
Amy Tang
Boris Freydin
Inna Chervoneva
Sameep Kadakia
Gordon F. Schwartz
Hallgeir Rui
Agnieszka K. Witkiewicz
Publication date
01-10-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1254-8

Other articles of this Issue 3/2011

Breast Cancer Research and Treatment 3/2011 Go to the issue

Letter to the Editor

Regarding the article “The p160 ER co-regulators predict outcome in ER negative breast cancer” by Spears, Oesterreich, Migliaccio et al. published in Breast Cancer Res Treat, March 2011

Clinical Trial

Oncological and cosmetic outcome in breast cancer patients undergoing “moving window” operation

Clinical Trial

The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures

Epidemiology

The association between chronic disease burden and quality of life among breast cancer survivors in Missouri

Clinical trial

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

Epidemiology

Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits